1575 results about "Globulin" patented technology

The invention provides a molecular marker related to immune traits of elephant male semi-fine wool sheep and a detection primer and application thereof, and belongs to the technical field of molecular assisted breeding. The nucleotide sequence of the molecular marker is shown as SEQ ID NO.1; the molecular marker comprises an SNP site, the SNP site is located at the 117th site of the molecular marker, the mutation basic group of the SNP site is A or G, and the immune globulin content of an individual male semi-fine wool sheep with the genotype of AG or GG at the SNP site is remarkably higher than that of an individual with the genotype of AA. The content of immune globulins IgA, IgG and IgM of an individual elephant male semi-fine-wool sheep can be judged according to the genotype of the molecular marker, the immune traits of the elephant male semi-fine-wool sheep can be rapidly and accurately evaluated, the high-immunity elephant male semi-fine-wool sheep can be screened, the molecular marker has important significance on early-stage auxiliary breeding of the elephant male semi-fine-wool sheep, the breeding period is remarkably shortened, and the breeding cost is reduced. The breeding efficiency is improved.

The invention belongs to the technical field of immunodetection, and discloses a rabbit monoclonal antibody mAb6 of an anti-mouse immune globulin G2a subtype (IgG2a) and application thereof. The rabbit monoclonal antibody mAb6 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence KSVYKNNY, the LCDR2 comprises an amino acid sequence GTN, and the LCDR3 comprises an amino acid sequence AGGYID; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence RFSLSNYR, the HCDR2 comprises an amino acid sequence IFTRGST, and the HCDR3 comprises an amino acid sequence ARGWNS. The rabbit monoclonal antibody disclosed by the invention can be combined with a mouse immune globulin G2a subtype (IgG2a) in a high-specificity manner, can be applied to immunodetection, and provides a basis for further preparation of engineering antibodies.

The invention provides a molecular marker related to immune traits of elephant male semi-fine wool sheep and application of the molecular marker, and belongs to the technical field of molecular marker application, and the nucleotide sequence of the molecular marker is shown as SEQ ID NO.1; the molecular marker comprises an SNP site, the SNP site is located at the 363rd site of the molecular marker, the basic group of the SNP site is T or C, and the immune globulin content of a male semi-fine wool sheep individual with the genotype of TC or CC at the SNP site is remarkably higher than that of a male semi-fine wool sheep individual with the genotype of TT. By detecting the genotype of the molecular marker SNP site related to the immune traits in the male semi-fine-wool sheep, the immune traits of the male semi-fine-wool sheep can be rapidly and accurately evaluated, and the molecular marker SNP site has important significance on early-stage auxiliary breeding of the male semi-fine-wool sheep.

The invention relates to the technical field of nutritional supplements. A traditional fat reducing method mainly comprises dieting, high-intensity exercise, medicine weight losing and the like. However, dieting may lead to malnutrition; high-intensity sports are difficult to insist, and sports injury is easily caused; in order to solve the technical problems, the invention discloses a fat-reducing nutritional composition capable of improving metabolism, and the fat-reducing nutritional composition can be used for solving the technical problems of severe side effects such as tachycardia, insomnia and the like caused by medicine weight loss. The composition comprises the following components in parts by weight: 13-21 parts of a bitter gourd extract, 15-31 parts of a garcinia cambogia extract, 13-17 parts of oat fibers, 17-23 parts of whey protein powder, 7-9 parts of linseed oil, 6-14 parts of a green tea extract, 9-15 parts of a calcium supplement and 15-19 parts of a purple perilla seed extract, and can provide energy for a user, supplement immune globulin, lactoferrin and a calcium source, improve the immunity of the user and improve the immunity of the user. The body metabolism level and immunocompetence are improved, absorption of fat in digestive tracts can be effectively inhibited, storage of fat in the body is reduced, fat consumption is promoted, and the fat reducing effect is achieved.

The invention provides an egg yolk globulin powder processing traceability method and system, and the method comprises the steps: carrying out the multi-node monitoring of each processing traceability process through a block chain technology, and carrying out the chain packaging of a processing dependency relationship between adjacent processing traceability processes and a time certificate provided by an authority timestamp service; generating a chained association block between adjacent processing nodes in each processing traceability process; performing digital signature on the initial identification code of the egg yolk globulin powder raw material, the processing node information of each processing traceability process and the combined data of the preorder data block hash value, and generating a credible voucher of each processing traceability process; jointly constructing a traceability node of each processing traceability process based on the credible voucher of each processing traceability process, the processing node information and the chained association block; and generating a tamper-resistant full-process tracing chain of the egg yolk globulin powder based on each tracing node. Based on the scheme, cross-link credible association in egg yolk globulin powder processing traceability can be realized.

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates method of treatment of cancer using novel bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47 and the second is specific for mesothelin (MSLN). In addition, the disclosure contains methods of treatment using novel bispecific antibodies in combination with anti-PD-1 antibody.

The invention discloses a composite microecological preparation as well as a preparation method and application thereof. The compound microecological preparation disclosed by the invention comprises lactobacillus casei, lactobacillus plantarum and saccharomyces cerevisiae. The application effect of the composite microecological preparation in cow breeding is remarkable, the optimal addition amount of the composite microecological preparation is 100 mL / cow / day, the production performance of lactating cows can be improved, the milk yield is improved by 3.30 kg / cow / day, the milk yield of 4% standard milk is improved by 3.78 kg / cow / day, the total protein is improved by 15.9%, the albumin is improved by 14.7%, the globulin is improved by 16.5%, and the somatic cell number is reduced by 52.6%; and pollutant emission can be reduced, including 37.2% of ammonia emission reduction and 28.7% of carbon dioxide emission reduction.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

The invention belongs to the technical field of immunology, and particularly relates to an anti-mandarin fish immune globulin D (IgD) monoclonal antibody as well as a preparation method and application thereof. The invention provides a hybridoma cell strain 5C7 capable of secreting an anti-fish IgD monoclonal antibody or an antigen binding fragment thereof for the first time, the hybridoma cell strain 5C7 is preserved in China Center for Type Culture Collection on January 16, 2025, and the preservation number is CCTCC NO: C202550. The anti-mandarin fish IgD monoclonal antibody or the antigen binding fragment thereof can be subjected to specific reaction with mandarin fish secreting type IgD protein and B cell surface film type IgD, can be applied to detection of IgD in a mandarin fish serum sample, and can also be applied to detection of IgD + B cell surface markers.

The invention belongs to the field of food processing, and discloses a preparation method and application of a targeted colon delivery polyunsaturated fatty acid grease microcapsule. 11S globulin in soybeans and Arabic gum are used as wall materials of the microcapsule, complex coacervation of the 11S globulin in the soybeans and the Arabic gum is induced under a certain pH condition, so that oil drops are wetted by a coacervate, a core-shell structure is formed, a coacervate phase is further stabilized through glucan to inhibit coalescence, and on the basis, the microcapsule is prepared. And tannic acid, polysaccharide and protein can form hydrogen bonds and generate hydrophobic interaction to further crosslink the condensed phase to obtain the microcapsule capable of resisting digestion of the stomach and the small intestine, so that colon delivery of polyunsaturated fatty acid is realized.

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA and its ligands, PD-1, PD-L1, and / or PD-L2.

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

The invention provides a culture medium and a culture method for culturing human primary B lymphoma cells. The culture medium for culturing the human primary B lymphoma cells, disclosed by the invention, is prepared from an anti-immune globulin M antibody, a recombinant human CD40 ligand, CpG oligodeoxynucleotide 2006, superoxide dismutase, interleukin-2, interleukin-21 and interleukin-4. By using the culture medium and the culture method disclosed by the invention, effective and rapid amplification of the B lymphoma cells can be realized, the B lymphoma cells obtained by amplification maintain pathological characteristics of patients, the culture success rate and the amplification rate of the B lymphoma cells are improved, and a research basis can be provided for personalized treatment of the patients. The invention also provides B lymphoma cells obtained by in-vitro culture of the culture medium, and a method and application of the B lymphoma cells in curative effect evaluation and screening of drugs.

Provided is an immunological measurement method for measuring a target substance in a sample, wherein an antigen-antibody reaction is performed at least once in the presence of an enzyme that specifically decomposes immunoglobulin A, abbreviated as IgA.

The invention discloses a preparation method of immunoglobulin composite liposome nanoparticles with a controlled release characteristic, and belongs to the field of food nutrition and functional factors. Cholesterol and sitosterol are creatively used as auxiliary supports of a lecithin liposome skeleton, the stability of an immunoglobulin liposome nanoparticle structure is improved, the slow release property in the simulation effect process is improved, and a pH response type hydrogel film formed based on electrostatic crosslinking is prepared from calcium alginate and chitosan. A more stable double-layer shell-core structure is formed, so that the stability of embedded immune globulin molecules in gastric juice is further improved, and fixed-point slow release in small intestines is realized.

The invention provides a serum free light chain detection reagent and method, and the reagent comprises a first reagent which comprises a reaction buffer solution and an anti-human IgG-Fab polyclonal antibody; the second reagent comprises an anti-human FLC polyclonal antibody marked by nano microspheres; wherein the anti-human IgG-Fab polyclonal antibody is used for blocking a cross reaction between a binding light chain in immune globulin in a sample and the anti-human FLC polyclonal antibody. The anti-human IgG-Fab polyclonal antibody is added into the reaction buffer solution, so that the problem of cross reaction between the anti-FLC polyclonal antibody and a light chain combined on immune globulin can be effectively solved, and meanwhile, the long-term stability of the reagent is ensured.

Extracellular protein degraders and compositions are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulin in vivo to treat disorders mediated by the extracellular protein.

The present invention provides a lipid nanoparticle comprising an entity that contains one or multiple sialic acid (SA) moieties, the entity is preferably a ganglioside, a ganglioside derivative, a ganglioside mimetic, or a combination thereof. The lipid nanoparticle of the present invention can effectively present SA moieties on the surface to bind Siglecs and complement factors to, inter alia, mitigate inflammation. The present invention also provides methods of using said lipid nanoparticle compositions described herein for pharmaceutical applications. For example, the lipid nanoparticles provided herein are useful for treating inflammatory and autoimmune diseases.

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

The invention relates method of treatment of cancer using novel bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47 and the second is specific for mesothelin (MSLN). In addition, the disclosure contains methods of treatment using novel bispecific antibodies in combination with anti-PD-1 antibody.

The invention provides a synthesis method of adsorption resin for removing immune globulin, and relates to a high polymer material synthesis technology, polyethylene glycol (PEG) or sulfobetaine (SBMA) is grafted through RAFT polymerization, the thickness of a grafting layer is 50-150nm, the nonspecific adsorption capacity of albumin is less than 5ng / cm < 2 >, photosensitive groups (such as phenyl azide) and ultraviolet light (254nm) are introduced to trigger crosslinking, and the coating shedding rate is less than 0.5% / time. According to the present invention, the cyclic stability is improved by 2 times, the Protein A directional capture antibody is grafted on the surface of the acrylic resin grafted with the polyethylene glycol or sulfobetaine, the IgG adsorption capacity achieves 150 mg / g, the specificity is more than 95%, the polyethylene glycol (PEG) is grafted on the surface of the magnetic particle by using ATRP / RAFT controllable polymerization, the organic solvent use amount is reduced by more than 80%, and the product adsorption capacity achieves 150 mg / g.

The invention discloses a method for preparing low-bitterness micromolecular bovine colostrum protein peptide powder by adopting a multi-stage membrane separation and enzyme membrane coupling combined technology, and belongs to the technical field of food processing. The preparation method comprises the following steps: firstly, dividing a colostrum component into components to be hydrolyzed by adopting a multi-stage membrane separation technology, namely casein intercepted by ceramic membrane microfiltration and lactoglobulin and lactalbumin filtered by an ultrafiltration membrane, and non-hydrolytic components, namely immune globulin and lactoferrin; the preparation method comprises the following steps: firstly, separating bovine coloctrum, then deeply hydrolyzing the separated lactoglobulin, milky white and casein flocculate with the molecular weight of less than 50kDa by adopting an enzyme membrane coupling technology, mixing with unhydrolyzed immunoglobulin and lactoferrin, and freeze-drying, so that the peptide content in the treated bovine coloctrum is more than 40%, the peptide content of 200-1000Da is more than 30%, the peptide content of 200-1000Da is more than 30%, and the peptide content of 200-1000Da is more than 30%. The preparation method is simple, the preparation dispersion time is within 10 s, no obvious bitter taste exists, the retention rate of immune globulin in bovine coloctrum reaches 90% or above, and the preparation method is suitable for large-scale industrial popularization.

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and / or CD8 (e.g., CD8α and / or CD8β)), and / or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and / or MHC II β chains) and / or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.